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The cancer stem cell (CSC) model posits that CSCs are a small, biologically distinct sub-
population of cancer cells in each tumor that have self-renewal and multi-lineage poten-
tial, and are critical for cancer initiation, metastasis, recurrence, and therapy- resistance. 
Numerous studies have linked CSCs to thyroid biology, but the candidate markers 
and signal transduction pathways that drive thyroid CSC growth are controversial, the 
origin(s) of thyroid CSCs remain elusive, and it is unclear whether thyroid CSC biology 
is consistent with the original hierarchical CSC model or the more recent dynamic CSC 
model. Here, we critically review the thyroid CSC literature with an emphasis on research 
that confirmed the presence of thyroid CSCs by in vitro sphere formation or in vivo tumor 
formation assays with dispersed cells from thyroid cancer tissues or bona fide thyroid 
cancer cell lines. Future perspectives of thyroid CSC research are also discussed.
Keywords: thyroid cancer, cancer stem cells, thyrosphere, aldehyde dehydrogenase, epithelial–mesenchymal 
transition
iNTRODUCTiON
The current consensus among cancer biologists is that cancer cellular heterogeneity can be explained 
in two ways. The first is the stochastic model, in which cancer development is initiated by accumula-
tion of genetic mutations in a single cancer cell, followed by distinct subsequent genetic events in 
different subpopulations of cells. The second is the cancer stem cell (CSC) model which proposes 
that there is a small, biologically distinct subpopulation of cancer cells, called CSCs, in each tumor 
that has self-renewal and multi-lineage potential. Although both models can explain the cellular 
heterogeneity of cancers, the two models are not mutually exclusive. The CSC model can also help 
address other poorly understood questions in cancer biology, such as recurrence, metastasis, and 
therapy-resistance. CSCs were first identified in acute myeloid leukemia in the 1990s, and then in 
solid cancers in the 2000s (1). In 2007, the first studies on thyroid CSCs and normal thyroid SCs 
were published (2–4), although there were some earlier papers describing expression of stemness 
markers in thyroid tissues.
As mentioned above, CSCs can self-renew and differentiate to produce phenotypically diverse 
cancer cells. In addition, they typically grow in vitro as spheres (referred to as thyrospheres in the 
case of the thyroid), occasionally exhibit chemo/radio-resistance, and share molecular similarities 
to embryonic and/or adult SCs. In general, the most reliable methods to prove the existence of CSCs 
experimentally are the in vivo tumor formation assay using immunedeficient mice or in vitro sphere 
formation assay using ultra-low attachment plates and serum-free culture. Here, we define thyroid 
CSCs as fulfilling at least one of these two conditions, although we are aware of the technological 
concerns surrounding both assays. For an example, in vivo tumor assay may just select the cells that 
can survive in new environments in mice.
In this regard, we critically review the articles published thus far that confirmed the presence of 
CSCs in thyroid follicular epithelial cell-derived cancers using cell lines or thyroid tumor cells and at 
February 2016 | Volume 7 | Article 202
Nagayama et al. Thyroid Cancer Stem Cells
Frontiers in Endocrinology | www.frontiersin.org
least one of the two methods mentioned above (5–19). The stud-
ies with cells that were found not to be of thyroid origin are not 
included in this review (20). It should be noted here that there are 
some confusions regarding FRO and WRO cells. Schweppe et al. 
(20) showed that FRO and WRO have wild-type (wt) BRAF and 
mutant (m) BRAFV600E, respectively, while our FRO have mBRAF 
and the short tandem repeat (STR) profiling data that are similar 
to those in WRO cells in Schweppe et al., and our WRO have wt 
BRAF and the unique STR profiling data (8, 21). It is at present 
unclear which are correct. In our opinion, it is unlikely that fol-
licular thyroid cancer (FTC)-derived WRO cells possess mBRAF. 
In addition, in Dima et  al. (14), cell aggregates were observed 
within 24 h, implying that they are likely spheroids (22), rather 
than true thyrospheres.
There is some confusion regarding the use of CSC terminology 
and the definition of CSCs. Some prefer to avoid the stem cell 
implications by referring to cells with the ability to initiate tumor 
growth and serial transplantation in immunocompromised mice 
as “tumor-initiating cells” (23) or “cancer propagating cells” (24). 
However, for convenience, we use CSC terminology throughout 
this review.
IN VITRO THYROSPHeRe AND IN VIVO 
TUMOR FORMATiON ASSAYS
As mentioned above, in vitro sphere and in vivo tumor formation 
assays are the most reliable approaches to prove the existence 
of CSCs. A perfect correlation between these two assays was 
reported in our studies using eight thyroid cancer cell lines (five 
anaplastic thyroid cancer (ATC) cell lines (FRO-mBRAF) (21), 
KTC2, KTC3, ACT1, and 8505C), two papillary thyroid cancer 
(PTC) cell lines (KTC1 and TPC1), and a FTC cell line (WRO-wt 
BRAF) (8). Similar correlations were also reported for aldehyde 
dehydrogenase (ALDH)+ cells from 33 out of 34 thyroid cancer 
samples (6).
The frequency of spherogenic cells has been reported to be 
variable; 2, 1.2, and 3.5% in dispersed cells from PTC, FTC, and 
ATC tumors, respectively (6), ~0.1% in dispersed cells from PTC 
tumors (7), 3.1–9.4% in four ATC cell lines (THJ-11T, -16T, -21T, 
and -29T) (10), and approximately 0–20% in the ATC cell lines 
mentioned previously (8). Thyrospheres generated from primary 
thyroid cancer cells expressed ALDH1A1 and CD44 (6), and 
some expressed stemness markers, Oct-4, ATP-binding cassette 
sub-family G member 2 (ABCG2), Sox-2, Nanog, CD133, and 
CD44 (7, 10, 11). Regarding differentiation markers, PTC-spheres 
expressed thyroid peroxidase (TPO), thyroglobulin, thyrotropin 
receptor, thyroid transcription factor 1 (TTF1), and Paired-box 
8 (Pax-8) at very low levels (6, 7), while ATC-spheres did not 
express these markers (6).
In vivo tumor formation was achieved by subcutaneous 
injection of 25,000 cells from PTCs (6) and subcutaneous and 
orthotopic injections of 500,000 ATC cells mentioned above 
(10), consistent with the frequency of tumorigenic cells being at 
least 0.0002–0.004%. However, in our study, as few as 50 cells 
from ATC cell lines (FRO-mBRAF, KTC3 and ACT1) were 
tumorigenic when admixed with growth factor-reduced matrigel 
(8). Enrichment of tumorigenic cells was successful in serial 
transplantation (10) and seemingly also by using an ALDH 
marker (6).
iDeNTiFiCATiON OF THYROiD CSCs
Identification of thyroid CSCs has been undertaken using CSC 
markers that were identified in other solid and hematopoietic 
malignancies. From a screen of eight thyroid cancer cell lines, 
we recently reported that there was no common thyroid CSC 
marker among 11 candidate markers [CD13, 15 (stage-specific 
embryonic antigen 1, SSEA-1), 24, 44, 44v, 90, 117, 133, 166, 
and 326 (epithelial cell adhesion molecule, EpCAM), and 
ALDH] (8). Nevertheless, there have been numerous papers 
reporting candidate markers for thyroid CSCs. Most studies 
have been done with a single marker, as summarized below. The 
usefulness and limitations of each marker have been discussed 
elsewhere (23, 25, 26).
Hoechst-Dye efflux (Side Population)
Side population cells have the ability to exclude the DNA 
binding dye Hoechst33342 via the ABCG2 drug transporter. 
It was first reported that small percentages of FRO-mBRAF 
(0.1%) and WRO-wt BRAF (0.02%) cells, but not TPC1 cells, 
were SP cells, but no functional analysis was undertaken (2). 
Similar data (0.43–0.83% positivity rates) were also reported 
using three ATC cell lines (C643, Hth74, and SW1736), 
but only SP cells from Hth74 formed thyrospheres (5). 
Nevertheless, this was the first paper showing sphere forma-
tion by thyroid cancer cells. However, this method should be 
applied carefully because of toxicity of the Hoechst dye and 
also UV (23, 26).
Drug Resistance
Long-term culture of Hth74 cells with a low concentration of the 
anti-cancer drug Doxorubicin led to the establishment of drug-
resistant cells (Hth74R), apparently as a result of expansion of 
pre-existing resistant cells rather than induction of resistant 
clones (5). The Hth74R cell line contained a much higher per-
centage of SP cells, and expressed higher levels of a stemness 
marker (Oct-4) and multidrug-resistance markers [ABCG2, 
multidrug resistance 1 (MDR1), and multidrug resistance-
associated protein 1 (MRP1)] compared to the parental Hth74 
cells (5). However, comparison of the efficacy of thyrosphere 
formation by parental Hth74 and drug-resistant Hth74R cells 
was not addressed. Although SP cells in the parental Hth74 
cell line were shown to be spherogenic as mentioned above, an 
increase in number of SP cells does not necessarily mean an 
increase in CSCs. Thus, this study may represent the establish-
ment of drug-resistant cell lines expressing higher levels of ABC 
transporters.
Expression of drug-resistance genes in CSCs may help explain 
the chemo-resistance of CSCs. However, CSCs usually proliferate 
slowly (even slower than non-CSCs) and are occasionally in the 
G0/G1 phase (i.e., dormant cells), which may contribute to the 
resistance to anti-cancer treatments, because quiescent cells are 
usually more drug-resistant than proliferative cells.
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Aldehyde Dehydrogenase
Aldehyde dehydrogenase plays roles in a variety of biological 
activities, including oxidation of toxic cellular aldehyde to 
carboxylic acids, biosynthesis of retinoic acid that binds to the 
heterodimeric transcription factor composed of retinoic acid 
receptor and retinoid x receptor, resistance to chemotherapeutic 
treatments [see reviews in Ref. (27–29) for more details]. As an 
example, ALDH1A3 was reported to be involved in the resist-
ance of K1 thyroid cancer cells to a FAK inhibitor (Y15) (30). By 
contrast, all-trans-retinoic acids, a product of ALDH catalysis, 
induced re-differentiation of thyroid cancer cells, consistent with 
ALDH as a potential therapeutic target (31).
In our opinion, the most elegant study of thyroid CSCs so 
far published is by Todaro et  al. (6). They showed that thyro-
spheres can be derived from dispersed cells from PTC, FTC, 
and ATC tumors. These spheres expressed ALDH1A1, CD44 
and stemness markers (Oct3/4 and Nanog), and ALDH+ cells 
were more spherogenic and tumorigenic than ALDH− cells. 
Thus, subcutaneous injection of 5,000 ALDH+, but not 25,000 
ALDH− cells, produced tumors in immunocompromised mice, 
and as few as 100 ALDH+ cells were also tumorigenic when 
injected orthotopically. This is the lowest cell number required 
for in vivo tumor formation in thyroid CSC studies published 
to date, except our study using matrigel (see above) (8). Reeb 
et  al. also reported successful tumor formation by orthotopic 
injection of 100 thyrosphere cells from ATC cell lines, THJ-11T 
and THJ-16T (18).
In our studies with thyroid cancer cell lines (8), ALDH positiv-
ity rates ranged from 6 to 85% in five ATC cell lines, 0–36% in two 
PTC cell lines, and 9% in one FTC cell line. Four ATC cell lines 
(FRO-mBRAF, ACT1 and KTC3, 8505C) developed thyrospheres 
in vitro and tumors in vivo in nude mice. Four other PTC, FTC, or 
ATC cell lines that were tested did not form thyrospheres in vitro, 
or tumors in  vivo. ALDH+ cells from the FRO-mBRAF, ACT1 
and KTC3 (but not 8505C) cell lines were more spherogenic than 
ALDH− cells. Of interest, ALDH expression was flexible, that is, 
ALDH+ cells could be derived from both ALDH+ and ALDH− 
cells. Furthermore, ALDH− cells were comprised of CD326 
(EpCAM)+ and CD326− cells, and the spherogenic activity of 
the former was higher than the latter, and comparable to that of 
ALDH+ FRO-mBRAF cells.
In the study by Todaro et al., ALDH1A1 was expressed in a small 
number of thyroid cancer cells, and the percentages of ALDHA1 
expressing cells (3% in FTC, 7% in PTC, and 16% in ATC) were 
positively correlated with aggressiveness (6). However, other 
studies, including ours (32, 33), reported much higher positivity 
rates for ALDH1A1 expression in normal and PTC tissues by 
immunohistochemistry using the same antibody. Although the 
reason(s) for these differences is/are at present unclear, and the 
latter data do not immediately dismiss the significance of ALDH 
as a CSC marker, Deng et al. concluded that “…ALDH should not 
be used as a CSC marker in tissue types that normally express a 
high level of ALDH1” (29, 33).
It should be noted here that of the 19 ALDH isozymes, 
ALDHA1 is the most predominantly expressed in both normal 
and cancerous thyroid tissues (32). However, ALDH1A3 is the 
most highly expressed isozyme in the K1 thyroid cancer cell line 
mentioned above (30).
CD133
CD133, also called prominin-1, is a five-trans membrane domain 
glycoprotein with unknown function and serves as a marker 
of stem cells in many normal and cancerous cells. Tseng et  al. 
isolated CD133+ cells from ATC tumors and the ATC cell lines, 
BHT-101, CAL-62, and 8505C. The CD133+ cells expressed 
stemness genes (Oct-4, Sox-2, and Nanog) and drug-resistance 
genes (ABCG2, MDR1, and MRP), were chemo-resistant, and 
formed thyrospheres in vitro and tumors in vivo (9). However, the 
positivity rates of CD133 were not described. Signal transducer 
and activation of transcription 3 (STAT3) signaling was activated 
in CD133+ cells compared to CD133− cells, and inhibition of 
STAT3 signaling with a JAK–STAT inhibitor (cucurbitacin I) 
decreased CD133+ cell proliferation in adherent culture, and 
sphere formation in suspension culture. However, the effect of 
cucurbitacin I was only specifically evaluated in the CD133+ 
fraction of cells in some experiments, and when studied in both 
fractions in other experiments, its effect on some cell functions 
did not appear to differ.
Furthermore, and more generally, the significance of CD133 as 
a CSC marker is controversial. When considering thyroid cancer 
specifically, CD133 mRNA was expressed in spheres from dis-
persed thyroid cancer cells (7, 13). CD133 protein was expressed 
in a FRO cell line (BRAF status unknown) but not in a TPC cell 
line (34), and not in eight cell lines, including FRO-mBRAF (8) 
and cancer-derived thyrospheres/tumors (6, 10).
Furthermore, CD133 data should be interpreted with caution 
because the antibodies against CD133 used in all the studies 
mentioned above is the clone AC133 (or CD133/1), which was 
previously reported to recognize only glycosylated versions of 
CD133 rather than unmodified CD133 protein isoforms (35).
CD44 and CD24
Ahn et al. focused their attention on CD44 and CD24, which 
are CSC markers for some cancers, including breast (11). Using 
cancer cell lines (the original TPC1 cell line and its deriva-
tives), they found higher numbers of CD44+/CD24− cells in the 
more aggressive cell lines (positivity rates being 86% in highly 
tumorigenic TPC-1Mice cells, >73% in moderately tumo-
rigenic TPC-1SC2 cells, >21% in parental, poorly tumorigenic 
TPC-1 cells). Subsequently, using dispersed cells from thyroid 
cancers, they determined that 4–70% cells were CD44+CD24−, 
the cells formed spheres, CD44+CD24− but not CD44+CD24+ 
cells from these spheres were spherogenic, and the cells derived 
from thyrospheres (at least 1 × 104) formed tumors following 
orthotopic injection.
In our study, CD24 was not expressed on TPC1 cells, but all 
WRO-wt BRAF, ACT1, and 8505C cells expressed CD24. CD44 
was expressed on 100% of cells in all the cell lines examined, and 
CD44v8-10, a CD44 variant, including exons 8–10, was expressed 
in two ATC cell lines (FRO-mBRAF and ACT1), both of which 
were spherogenic/tumorigenic (8). CD44v8-10 contributes to 
protection from reactive oxygen species-induced cellular stress, 
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a typical CSC characteristic, by producing reduced glutathione, 
the primary intracellular antioxidant (36).
Stage-Specific embryonic Antigen-1  
(or CD15)
Stage-specific embryonic antigen-1 was expressed at variable 
levels in all of the cell lines examined (ML1, FTC236, FTC238, 
T238, SW1736, and TPC1; 3–9%) in one study (16), but only in 
one (FRO-mBRAF) of eight cell lines in another report (8). In 
the former, SSEA-1+ cells expressed stemness and epithelial–
mesenchymal transition (EMT) (see below) markers, and 104 
SSEA-1+ cells produced subcutaneous tumors, whereas SSEA-
1− cells did not. Of interest, SSEA expression exhibited plastic-
ity, suggesting that SSEA+ and SSEA− cells were in a dynamic 
equilibrium (see below).
iNDUCTiON OF CSCs FROM BULK 
CANCeR CeLL PRePARATiONS
Epithelial–mesenchymal transition was originally recognized to 
be a vital process for morphogenesis in embryonic development, 
and was recently implicated in invasion/metastasis of malignan-
cies and the biology of CSCs (37). Indeed, in our studies (8, 12), 
although the cells with epithelial phenotype (ACT1) and those 
with mesenchymal phenotype (FRO-mBRAF and KTC3) were 
both capable of forming thyrospheres, the spherogenicity was 
higher in the latter.
A correlation between forced induction of EMT status and 
stemness was reported in two articles, which used the transcrip-
tion factors SNAIL (12), and hypoxia-inducible factor (HIF)-1α 
(15), as EMT-inducers in epithelial type ACT1 and FTC133 cells, 
respectively. EMT phenotypes, such as decreased expression 
of epithelial markers (e.g., E-cadherin), increased expression 
of mesenchymal markers (e.g., vimentin), and spindle-shaped 
appearance, were induced in both studies. In one study, EMT 
induced by overexpression of SNAIL in ACT1 led to an increase 
in thyrosphere forming ability in a small fraction of ALDH− cells, 
indicating a link between EMT and CSCs only in ALDH− cells (12). 
In the other report, EMT induction by HIFα was accompanied by 
high invasiveness and increased numbers of sphere-forming SP 
cells expressing the stemness gene Oct-4, and the drug-resistance 
gene ABCG2 (15).
However, in the latter, the morphologies of the parental and 
transfected cells (cobblestone- and spindle-shaped appearances, 
respectively) and those of SP and non-SP cells isolated from 
transfected cells (cobblestone- and spindle-shaped appearances, 
respectively) in adherent culture could not be reconciled. Similar 
data were also presented in a previous paper by the same authors 
(5). Furthermore, because an EMT phenotype is generally 
observed at the invasive fronts of thyroid cancer tissues (38, 39), 
while HIF-1α is usually expressed in cells in hypoxic, central 
regions of cancers, the significance of HIFα-induction of EMT in 
thyroid cancers is unclear.
Very recently, the significance of EMT in invasion and metas-
tasis was challenged, and instead implicated in the development 
of chemo-resistance (40).
COMPARiSON OF NORMAL THYROiD SCs 
AND THYROiD CSCs
Thyrospheres have been generated from normal thyroid 
cells as well as those from Graves’ and nodular goiter tissues 
(4, 13, 41). SP cells purified from nodular goiters (Oct-4+ and 
thyroid differentiation markers−) did not proliferate indepen-
dently, while the bulk of dispersed cells from the same tissues, 
which was contaminated with endodermal cells, did produce 
thyrospheres (4), suggesting that co-existing endodermal cells 
may be important as niche cells. By contrast, as mentioned 
above, some cancer cell lines and cancer cells can form spheres 
independently.
A comparison of normal thyroid SCs and thyroid CSCs was 
performed in detail by Giani et  al. (13). PTC-CSCs exhibited 
the higher clonogenic potential, forming larger, more irregular 
spheres, as compared to normal SCs. PTC–CSCs also expressed 
higher levels of stemness markers (Oct-4, Sox-2, and ABCG2) and 
an EMT marker (vimentin), lower levels of some differentiation 
markers (Pax-8 and TTF1), and showed poorer differentiation 
efficiency than normal SCs. Several genes and gene families were 
differentially expressed between normal SCs and CSCs, including 
Wnt pathway, whose expression levels were higher in CCSs than 
normal SCs.
SiGNALiNG PATHwAYS CONTROLiNG 
CSC PROPeRTieS
The successful development of CSC-targeted therapies may be 
achieved by targeting CSC-specific cell surface markers or signal 
transduction pathways. In this regard, it is important to delineate 
the signaling pathways controlling CSC initiation and growth. 
The following three different intracellular signal transduction 
pathways are important mediators of thyroid CSC biology.
The insulin-Like Growth Factor-i (iGF-i) 
Pathway
Papillary thyroid cancer-spheres expressed insulin-like growth 
factor (IGF)-I/II and IGF-IR, and stimulation of this signaling 
pathway increased the number and size of spheres (7).
The Sonic Hedgehog Signaling Pathway
The sonic hedgehog (Shh) pathway is activated in some ATC cell 
lines (SW1736, BCPAP, and KAT-18), and pathway inhibitors 
and shRNA-mediated suppression of Shh signaling molecules 
inhibited ALDH activity and thyrosphere formation (17). The 
importance of Shh was also demonstrated by increased sphere 
formation by overexpression of the Shh pathway effector mol-
ecule, Gli1. However, a caveat of these experiments is that it was 
unclear whether the effects of these inhibitors and shRNA were 
CSC-specific.
The STAT3 Signaling Cascade
This pathway was activated in ATC-CD133+ cells, and the sup-
pressive effect of a JAK–STAT inhibitor cucurbitacin I on CSC 
characteristics was shown (9).
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Others
The therapeutic effects of targeting other stem cell markers, 
including Sox-2 or CD44 were reported using bulk cancer cells, 
although the CSC fractions were not studied in isolation (42, 43).
CeLL-OF-ORiGiN OF CSCs AND 
HieRARCHiCAL veRSUS DYNAMiC 
MODeLS
The cellular origins of thyroid CSCs are unknown, and it remains 
to be determined whether they are derived from normal SCs, 
progenitor cells or mature thyroid cells. The thyroid fetal cell 
carcinogenesis hypothesis (44) was proposed over a decade ago, 
but has not yet been substantiated. Experiments with the thyroid 
cancer mouse model (BRAF-V600Ef/wt; TPO-Cre) demonstrated 
that cancer cells developed from TPO-expressing (i.e., at least 
partially differentiated) thyroid cells and showed EMT charac-
teristics, consistent with the derivation of CSCs from differenti-
ated thyroid cells via EMT, rather than from normal SCs (45). 
However, these data should be interpreted with caution because 
human thyroid sphere cells and mouse thyroid SP cells express 
low levels of TPO (3, 13).
The original and somewhat rigid hierarchical CSC model pro-
posed that CSCs lie at the apex of the hierarchical organization of 
cancer tissues, and have abilities to self-renew and unidirection-
ally differentiate to progenitor and mature cancer cells. However, 
this model has recently been challenged. In the dynamic CSC 
model, CSC phenotypes are more flexible, and cells interconvert 
between CSCs and non-CSCs spontaneously, or in response to 
particular conditions (46, 47). A good example is EMT induction 
of CSCs as mentioned above. Furthermore, it was demonstrated 
that ALDH+ CSCs (8) and SSEA-1+ CSCs (16) exhibited plastic-
ity by spontaneously transitioning from one state to the other in 
dynamic equilibrium. Thus, the data so far obtained for thyroid 
cancers are more consistent with the dynamic CSC model.
The dynamics of CSC properties have been demonstrated in 
several other cancers. Some showed spontaneous equilibrium 
between CSCs and non-CSCs (48, 49), and others showed induc-
tion of CSC characteristics by particular signals (e.g., EMT and 
IL-6) (37, 50).
DiSCUSSiON
In this review, we have described the significant progress that 
has been made in addressing the biology of thyroid CSCs. 
However, numerous questions remain unanswered and new 
issues have arisen as the field has expanded. We discuss some 
of these issues below.
Numerous CSC markers have been identified to date (SP, drug 
resistance, expression of ALDH, CD133, CD24, and SSEA  1). 
With respect to these markers, thyroid cancers are similar to 
other malignancies in terms of expression of CD44+CD24−, 
ALDH+, and CD133+ (breast cancers), CD133+ and ALDH+ 
(colon cancers), and CD44highESAlow-EMT and CD44highESAhigh-
EMT in oral squamous cell carcinomas (see Ref. (8) for more 
details). However, for thyroid cancers (and most other tumors), 
it is unclear whether these multiple markers represent discrete or 
overlapping CSC subpopulations or whether there are other as yet 
unidentified definitive CSC markers. It also remains to be clari-
fied whether different tumors express distinct and characteristic 
CSC markers, or individual cancers contain multiple different 
types of CSCs.
It is important to acknowledge that the data summarized in 
this review may at least in part reflect experimental artifacts 
relating to experimental conditions and/or cell types being 
studied, and technical variability across different laboratories. 
For example, one paper reported thyrosphere formation only 
from ATC cell lines, not differentiated thyroid cancer (DTC) 
cell lines (8), while others described thyrospheres from cell 
lines or dispersed cells from DTCs (6, 11, 13). Also ALDH1A1 
positivity rates in normal/cancerous thyroid tissues/cells and 
expression levels of CD133, SSEA-1, and CD24 in thyroid 
cancer cells varied among different studies. Furthermore, 
improvements in the efficiency of CSC isolation are clearly 
necessary because even after CSC enrichment using a par-
ticular marker, only a small fraction of the marker+ cells are 
spherogenic/tumorigenic, consistent with only partial purifi-
cation of CSCs.
Similarly, multiple signaling pathways, such as IGF-1, STAT3, 
and Shh, play a role in regulating thyroid CSC growth. STAT3 
and Shh signaling are linked to the biology of CD133 and ALDH, 
respectively, but the relative importance of the crosstalk between 
these pathways remains enigmatic. Furthermore, although 
several reports have pointed to the potential of some drugs 
and shRNA for CSC therapy, the specificities and effectiveness 
of these agents have not been fully evaluated. Importantly, the 
relative effects of each agent on CSCs and non-CSCs (or at least 
the bulk of cells) should be carefully addressed. In our opinion, 
“CSC-targeted therapies” should show specific killing of CSCs, 
and not non-CSCs, including, in particular, normal SCs. We 
believe that a therapeutic agent that kills both CSCs and non-
CSCs is not CSC-targeted.
Finally, whether thyroid CSC biology reflects the original, 
hierarchical CSC model or the more flexible, dynamic model is 
another important issue. The data acquired so far (albeit from 
only two cell lines) indicate that thyroid CSC biology is more 
consistent with the dynamic model. In this regard, studies on 
genetic/epigenetic/environmental signaling networks regulat-
ing CSC plasticity will be intriguing. In addition, plasticity of 
CSC phenotype may challenge the idea that the study of CSCs 
is pivotal for the development of novel treatment modalities 
for thyroid cancer. CSC-targeted therapy may not be curative 
because of spontaneous reprograming from non-CSCs to CSCs. 
Overall, although the potential of CSC-targeted therapy for 
treating thyroid cancer remains tantalizing, further studies are 
necessary to comprehensively understand thyroid CSC biology 
and ultimately achieve the goal of curing thyroid cancer patients 
by CSC-targeted therapy.
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